Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 24:13:1151701.
doi: 10.3389/fonc.2023.1151701. eCollection 2023.

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Keren Rouvinov  1   2 , Eran Levanon  3 , Avivit Peer  4 , Michal Sarfaty  5 , David Sarid  6 , Victoria Neiman  7 , Eduard Grikshtas  8 , Eli Rosenbaum  7 , Igal Kushnir  9 , Barak Talmor  4 , Michael Friger  2 , Yonaton Zarbiv  10 , Eli Gez  11 , Hadas Dresler  12 , Walid Shalata  1 , Amichay Meirovitz  1   2 , Noa Shani Shrem  1 , Alexander Yakobson  1   2 , Wilmosh Mermershtain  1 , Daniel Keizman  6
Affiliations

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Keren Rouvinov et al. Front Oncol. .

Abstract

Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival. These FGFR genomic alterations are uncommon. Thus, real-world data on erdafitinb use is scant. We herein describe erdafitinib treatment outcome in a real world patient cohort.

Methods: We retrospectively reviewed the data of patients treated with erdafitinib from 9 Israeli medical centers.

Results: Twenty-five patients with metastatic urothelial carcinoma (median age 73, 64% male, 80% with visceral metastases) were treated with erdafitinib between January 2020 to October 2022. A clinical benefit (complete response 12%, partial response 32%, stable disease 12%) was seen in 56%. Median progression-free survival was 2.7 months, and median overall survival 6.73 months. Treatment related toxicity ≥ grade 3 occurred in 52%, and 32% discontinued therapy due to adverse events.

Conclusions: Erdafitinib therapy is associated with a clinical benefit in the real world setting, and associated with similar toxicity as reported in prospective clinical trials.

Keywords: erdafitinib; fibroblast growth factor receptor (FGFR) inhibitor; metastatic urothelial carcinoma; real-world analysis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Type of response to Erdafirinib.
Figure 2
Figure 2
Progression–free survival.
Figure 3
Figure 3
Overall survival.
Figure 4
Figure 4
A swimmer plot of therapy response and duration.
See this image and copyright information in PMC

References

    1. Monteiro FSM, Silva AGE, Gomes AJP de S, Dutra C, Ferreira NO, Mariano RC, et al. . Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real–world evidence from an expanded access program. Ther Adv Med Oncol (2021) 13:175883592110154. doi: 10.1177/17588359211015499 - DOI - PMC - PubMed
    1. Seront E, Catala G, Dermine A, Lejeune S, Rysselinck S. Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. Future Sci OA (2018) 4(10):FSO341. doi: 10.4155/fsoa-2018-0033 - DOI - PMC - PubMed
    1. Loriot Y, Necchi A, Park SH, Garcia–Donas J, Huddart R, Burgess E, et al. . Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med (2019) 381(4):338–48. doi: 10.1056/NEJMoa1817323 - DOI - PubMed
    1. Siefker–Radtke AO, Necchi A, Park SH, García–Donas J, Huddart RA, Burgess EF, et al. . Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long–term follow–up of a phase 2 study. Lancet Oncol (2022) 23(2):248–58. doi: 10.1016/S1470-2045(21)00660-4 - DOI - PubMed
    1. Belmunt J, de Wit R, Vaughn DJ, Fradet Y, Vogelzang NJ, Climent MA, et al. . Pembrolizumab as second–line therapy for advanced urothelial carcinoma. N Engl J Med (2017) 376(11):1015–26. doi: 10.1056/NEJMoa1613683 - DOI - PMC - PubMed